Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.28) by 46.43 percent. This is a 76.56 percent increase over losses of $(0.64) per share from the same period last year.  The company reported quarterly sales of $3.83 million which beat the analyst consensus estimate of $2.07 million by 84.83 percent.

IMNM

NDAQ

<p>Immunome (NASDAQ:IMNM) reported better-than-expected Q4 results, with adjusted EPS of $(0.15) beating the estimate of $(0.28) by 46.43%. Sales of $3.83M also surpassed the estimate of $2.07M by 84.83%.</p>

Immunome Q4 Adj EPS $(0.15) Beats $(0.28) Estimate, Sales $3.83M Beat $2.07M Estimate